Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults

Neurobiology of Aging

Volumn 35, Issue 3, 2014, Pages 614-622

  Mattsson, Niklas ^a,b,c   Insel, Philip ^a   Nosheny, Rachel ^a   Trojanowski, John Q ^d   Shaw, Leslie M ^d   Jack, Clifford R ^e   Tosun, Duygu ^a,c   Weiner, Michael ^a,c  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e MAYO CLINIC   (United States)

Author keywords

Alzheimer's disease; Atrophy; Biomarkers; Cerebrospinal fluid; Longitudinal

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN C3; APOLIPOPROTEIN D; BETA2 GLYCOPROTEIN 1; BRAIN PROTEIN; PROTEIN S100B; STROMELYSIN; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CELL ACTIVITY; COGNITION; FEMALE; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MICROGLIA; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN INTERACTION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; SYNAPSE; TEMPORAL CORTEX; VERY ELDERLY;

ALZHEIMER'S DISEASE; ATROPHY; BIOMARKERS; CEREBROSPINAL FLUID; LONGITUDINAL;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS; ATROPHY; BRAIN; COGNITION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; PEPTIDE FRAGMENTS; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT; TAU PROTEINS;

EID: 84889600279     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.08.027     Document Type: Article

References (37)

1. Abdi F., Quinn J.F., Jankovic J., McIntosh M., Leverenz J.B., Peskind E., Nixon R., Nutt J., Chung K., Zabetian C., Samii A., Lin M., Hattan S., Pan C., Wang Y., Jin J., Zhu D., Li G.J., Liu Y., Waichunas D., Montine T.J., Zhang J. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J.Alzheimers Dis 2006, 9:293-348.
2. Bateman R.J., Xiong C., Benzinger T.L., Fagan A.M., Goate A., Fox N.C., Marcus D.S., Cairns N.J., Xie X., Blazey T.M., Holtzman D.M., Santacruz A., Buckles V., Oliver A., Moulder K., Aisen P.S., Ghetti B., Klunk W.E., McDade E., Martins R.N., Masters C.L., Mayeux R., Ringman J.M., Rossor M.N., Schofield P.R., Sperling R.A., Salloway S., Morris J.C. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N.Engl. J. Med 2012, 367:795-804.
3. Blennow K., Hampel H., Weiner M., Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nature Rev. Neurol 2010, 6:131-144.
4. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259.
5. Braak H., Thal D.R., Ghebremedhin E., Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J.Neuropathol. Exp. Neurol 2011, 70:960-969.
6. Buerger K., Ewers M., Pirttila T., Zinkowski R., Alafuzoff I., Teipel S.J., DeBernardis J., Kerkman D., McCulloch C., Soininen H., Hampel H. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006, 129:3035-3041.
7. Chételat G. Alzheimer disease: Aβ-independent processes-rethinking preclinical AD. Nature Rev. Neurol 2013, 9:123-124.
8. Chételat G., Villemagne V.L., Villain N., Jones G., Ellis K.A., Ames D., Martins R.N., Masters C.L., Rowe C.C. Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition. Neurology 2012, 78:477-484.
9. Craig-Schapiro R., Kuhn M., Xiong C., Pickering E.H., Liu J., Misko T.P., Perrin R.J., Bales K.R., Soares H., Fagan A.M., Holtzman D.M. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS One 2011, 6:e18850.
10. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., LaRossa G.N., Spinner M.L., Klunk W.E., Mathis C.A., DeKosky S.T., Morris J.C., Holtzman D.M. Inverse relation between invivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol 2006, 59:512-519.
11. Fagan A.M., Perrin R.J. Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark. Med 2012, 6:455-476.
12. Fenton H., Finch P.W., Rubin J.S., Rosenberg J.M., Taylor W.G., Kuo-Leblanc V., Rodriguez-Wolf M., Baird A., Schipper H.M., Stopa E.G. Hepatocyte growth factor (HGF/SF) in Alzheimer's disease. Brain Res 1998, 779:262-270.
13. Fischl B., Salat D.H., Busa E., Albert M., Dieterich M., Haselgrove C., van der Kouwe A., Killiany R., Kennedy D., Klaveness S., Montillo A., Makris N., Rosen B., Dale A.M. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002, 33:341-355.
14. Fischl B., van der Kouwe A., Destrieux C., Halgren E., Ségonne F., Salat D.H., Busa E., Seidman L.J., Goldstein J., Kennedy D., Caviness V., Makris N., Rosen B., Dale A.M. Automatically parcellating the human cerebral cortex. Cereb. Cortex 2004, 14:11-22.
15. Fjell A.M., Walhovd K.B., Fennema-Notestine C., McEvoy L.K., Hagler D.J., Holland D., Blennow K., Brewer J.B., Dale A.M. Brain atrophy in healthy aging is related to CSF levels of A{beta}1-42. Cereb Cortex 2010 Sep, 20:2069-2079.
16. He X., Jittiwat J., Kim J.-H., Jenner A.M., Farooqui A.A., Patel S.C., Ong W.-Y. Apolipoprotein D modulates F2-isoprostane and 7-ketocholesterol formation and has a neuroprotective effect on organotypic hippocampal cultures after kainate-induced excitotoxic injury. Neurosci. Lett 2009, 455:183-186.
17. Henneman W.J.P., Vrenken H., Barnes J., Sluimer I.C., Verwey N.A., Blankenstein M.A., Klein M., Fox N.C., Scheltens P., Barkhof F., van der Flier W.M. Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. Neurology 2009, 73:935-940.
18. Hu W.T., Chen-Plotkin A., Arnold S.E., Grossman M., Clark C.M., Shaw L.M., Pickering E., Kuhn M., Chen Y., McCluskey L., Elman L., Karlawish J., Hurtig H.I., Siderowf A., Lee V.M., Soares H., Trojanowski J.Q. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol 2010, 119:669-678.
19. Hu W.T., Holtzman D.M., Fagan A.M., Shaw L.M., Perrin R., Arnold S.E., Grossman M., Xiong C., Craig-Schapiro R., Clark C.M., Pickering E., Kuhn M., Chen Y., Van Deerlin V.M., McCluskey L., Elman L., Karlawish J., Chen-Plotkin A., Hurtig H.I., Siderowf A., Swenson F., Lee V.M., Morris J.C., Trojanowski J.Q., Soares H. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 2012, 79:897-905.
20. Jack C.R., Bernstein M.A., Fox N.C., Thompson P., Alexander G., Harvey D., Borowski B., Britson P.J., L Whitwell J., Ward C., Dale A.M., Felmlee J.P., Gunter J.L., Hill D.L.G., Killiany R., Schuff N., Fox-Bosetti S., Lin C., Studholme C., DeCarli C.S., Krueger G., Ward H.A., Metzger G.J., Scott K.T., Mallozzi R., Blezek D., Levy J., Debbins J.P., Fleisher A.S., Albert M., Green R., Bartzokis G., Glover G., Mugler J., Weiner M.W. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J.Magn. Reson. Imaging 2008, 27:685-691.
21. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010, 9:119-128.
22. Motta M., Imbesi R., Di Rosa M., Stivala F., Malaguarnera L. Altered plasma cytokine levels in Alzheimer's disease: correlation with the disease progression. Immunol. Lett 2007, 114:46-51.
23. Navarro A., Ordóñez C., Martínez E., Pérez C., Astudillo A., Tolivia J. Apolipoprotein D expression absence in degenerating neurons of human central nervous system. Histol. Histopathol 2008, 23:995-1001.
24. Oh H., Madison C., Villeneuve S., Markley C., Jagust W.J. Association of gray matter atrophy with age, β-amyloid, and cognition in aging. Cereb. Cortex 2013, 10.1093/cercor/bht017.
25. Ohrfelt A., Andreasson U., Simon A., Zetterberg H., Edman A., Potter W., Holder D., Devanarayan V., Seeburger J., Smith A.D., Blennow K., Wallin A. Screening for new biomarkers for subcortical vascular dementia and Alzheimer's disease. Dement. Geriatr. Cogn. Dis. Extra 2011, 1:31-42.
26. Olsson A., Vanderstichele H., Andreasen N., De Meyer G., Wallin A., Holmberg B., Rosengren L., Vanmechelen E., Blennow K. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin. Chem 2005, 51:336-345.
27. Pimplikar S.W., Nixon R.A., Robakis N.K., Shen J., Tsai L.-H. Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. J.Neurosci 2010, 30:14946-14954.
28. Reuter M., Schmansky N.J., Rosas H.D., Fischl B. Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage 2012, 61:1402-1418.
29. Rusinek H., De Santi S., Frid D., Tsui W.-H., Tarshish C.Y., Convit A., de Leon M.J. Regional brain atrophy rate predicts future cognitive decline: 6-Year longitudinal MR imaging study of normal aging. Radiology 2003, 229:691-696.
30. Savva G.M., Wharton S.B., Ince P.G., Forster G., Matthews F.E., Brayne C. Age, neuropathology, and dementia. N.Engl. J. Med 2009, 360:2302-2309.
31. Schott J.M., Bartlett J.W., Fox N.C., Barnes J. Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1-42. Ann. Neurol 2010, 68:825-834.
32. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Clark C.M., Aisen P.S., Petersen R.C., Blennow K., Soares H., Simon A., Lewczuk P., Dean R., Siemers E., Potter W., Lee V.M., Trojanowski J.Q. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol 2009, 65:403-413.
33. Sluimer J.D., Bouwman F.H., Vrenken H., Blankenstein M.A., Barkhof F., van der Flier W.M., Scheltens P. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol. Aging 2010, 31:758-764.
34. Terrisse L., Poirier J., Bertrand P., Merched A., Visvikis S., Siest G., Milne R., Rassart E. Increased levels of apolipoprotein D in cerebrospinal fluid and hippocampus of Alzheimer's patients. J.Neurochem 1998, 71:1643-1650.
35. Thambisetty M., Simmons A., Hye A., Campbell J., Westman E., Zhang Y., Wahlund L.O., Kinsey A., Causevic M., Killick R., Kloszewska I., Mecocci P., Soininen H., Tsolaki M., Vellas B., Spenger C., Lovestone S. Plasma biomarkers of brain atrophy in Alzheimer's disease. PLoS One 2011, 6:e28527.
36. Tosun D., Schuff N., Shaw L.M., Trojanowski J.Q., Weiner M.W., Alzheimer's Disease NeuroImaging Initiative Relationship between CSF biomarkers of Alzheimer's disease and rates of regional cortical thinning in ADNI data. J.Alzheimer Dis 2011, 26(suppl 3):77-90.
37. Weigand S.D., Vemuri P., Wiste H.J., Senjem M.L., Pankratz V.S., Aisen P.S., Weiner M.W., Petersen R.C., Shaw L.M., Trojanowski J.Q., Knopman D.S., Jack C.R. Transforming CSF A?42 measures into calculated Pittsburgh Compound B (PIBcalc) units of brain A? amyloid. Alzheimers Dement 2011, 7:133-141.